MAP kinases in inflammatory bowel disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

MAP kinases in inflammatory bowel disease. / Coskun, Mehmet; Olsen, Jørgen; Seidelin, Jakob Benedict; Nielsen, Ole Haagen.

In: Clinica Chimica Acta, Vol. 412, No. 7-8, 2011, p. 513-20.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Coskun, M, Olsen, J, Seidelin, JB & Nielsen, OH 2011, 'MAP kinases in inflammatory bowel disease', Clinica Chimica Acta, vol. 412, no. 7-8, pp. 513-20. https://doi.org/10.1016/j.cca.2010.12.020

APA

Coskun, M., Olsen, J., Seidelin, J. B., & Nielsen, O. H. (2011). MAP kinases in inflammatory bowel disease. Clinica Chimica Acta, 412(7-8), 513-20. https://doi.org/10.1016/j.cca.2010.12.020

Vancouver

Coskun M, Olsen J, Seidelin JB, Nielsen OH. MAP kinases in inflammatory bowel disease. Clinica Chimica Acta. 2011;412(7-8):513-20. https://doi.org/10.1016/j.cca.2010.12.020

Author

Coskun, Mehmet ; Olsen, Jørgen ; Seidelin, Jakob Benedict ; Nielsen, Ole Haagen. / MAP kinases in inflammatory bowel disease. In: Clinica Chimica Acta. 2011 ; Vol. 412, No. 7-8. pp. 513-20.

Bibtex

@article{5d20d0d7c8b3420a932d7d752210c80c,

title = "MAP kinases in inflammatory bowel disease",

abstract = "The mammalian family of mitogen-activated protein kinases (MAPKs) is activated by diverse extracellular and intracellular stimuli, and thereby they play an essential role in connecting cell-surface receptors to changes in transcriptional programs. The MAPK signaling pathways regulate a wide range of cellular activities and have been implicated in the pathogenesis of several diseases, including inflammatory bowel disease (IBD). This review summarizes recent findings on the regulatory mechanism of MAPK signaling pathways, focusing on nuclear targets and their role in IBD. Finally, it summarizes how these signaling pathways have been exploited for the development of therapeutics and discuss the current knowledge of potential MAPK inhibitors and their anti-inflammatory effects in clinical trials related to IBD.",

author = "Mehmet Coskun and J{\o}rgen Olsen and Seidelin, {Jakob Benedict} and Nielsen, {Ole Haagen}",

year = "2011",

doi = "10.1016/j.cca.2010.12.020",

language = "English",

volume = "412",

pages = "513--20",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

number = "7-8",

}

RIS

TY - JOUR

T1 - MAP kinases in inflammatory bowel disease

AU - Coskun, Mehmet

AU - Olsen, Jørgen

AU - Seidelin, Jakob Benedict

AU - Nielsen, Ole Haagen

PY - 2011

Y1 - 2011

N2 - The mammalian family of mitogen-activated protein kinases (MAPKs) is activated by diverse extracellular and intracellular stimuli, and thereby they play an essential role in connecting cell-surface receptors to changes in transcriptional programs. The MAPK signaling pathways regulate a wide range of cellular activities and have been implicated in the pathogenesis of several diseases, including inflammatory bowel disease (IBD). This review summarizes recent findings on the regulatory mechanism of MAPK signaling pathways, focusing on nuclear targets and their role in IBD. Finally, it summarizes how these signaling pathways have been exploited for the development of therapeutics and discuss the current knowledge of potential MAPK inhibitors and their anti-inflammatory effects in clinical trials related to IBD.

AB - The mammalian family of mitogen-activated protein kinases (MAPKs) is activated by diverse extracellular and intracellular stimuli, and thereby they play an essential role in connecting cell-surface receptors to changes in transcriptional programs. The MAPK signaling pathways regulate a wide range of cellular activities and have been implicated in the pathogenesis of several diseases, including inflammatory bowel disease (IBD). This review summarizes recent findings on the regulatory mechanism of MAPK signaling pathways, focusing on nuclear targets and their role in IBD. Finally, it summarizes how these signaling pathways have been exploited for the development of therapeutics and discuss the current knowledge of potential MAPK inhibitors and their anti-inflammatory effects in clinical trials related to IBD.

U2 - 10.1016/j.cca.2010.12.020

DO - 10.1016/j.cca.2010.12.020

M3 - Journal article

C2 - 21185271

VL - 412

SP - 513

EP - 520

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 7-8

ER -

ID: 33232373